A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

NCT07357740 · Not yet recruiting

Last updated 2026-05-28

This study is testing two different versions of an injectable diabetes medication called CagriSema in adults with type 2 diabetes to see how it affects their blood sugar levels.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 400 people Planned (estimated).

Who can join Ages 18–64 · all sexes

Timeline Started 2026-08 · est. completion 2027-10

Where 61 sites · Denmark, Greece, Malaysia, Serbia, Slovakia, Spain, Thailand, United States

What this study is testing ClinicalTrials.gov NCT07357740 ↗

Description as written by the study sponsor.

This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.

Treatments tested

CagriSema Drug

Cagrilintide and Semaglutide will be administered subcutaneously using device 1 or device 2.
Placebo CagriSema Drug

Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.

Main thing measured	Change in glycated haemoglobin (HbA1c)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07357740 ↗